Hyo Joo Lim
Family · Los Angeles, CANPI 1023572039
Payments from drug & device makers
Across 150 payments — averaging $25.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$770
- Astellas Pharma US Inc$742
- Sumitomo Pharma America, Inc.$467
- Teleflex LLC$423
- AbbVie$276
- Boston Scientific$245
- plus $961 from 14 others
What the payments were for
- Food & beverage$3,54991%
- Education$3359%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 31 | $770 |
| Astellas Pharma US Inc | 30 | $742 |
| Sumitomo Pharma America, Inc. | 21 | $467 |
| Teleflex LLC | 16 | $423 |
| AbbVie | 11 | $276 |
| Boston Scientific | 6 | $245 |
| Bayer | 6 | $167 |
| Cardiva Medical, Inc. | 6 | $142 |
| Urovant Sciences Inc | 8 | $135 |
| Amgen | 1 | $125 |
| Tolmar, Inc. | 3 | $78 |
| Biosense Webster, Inc. | 2 | $77 |
| Abiomed | 2 | $64 |
| Alnylam Pharmaceuticals Inc. | 1 | $35 |
| Urogen Pharma, Inc. | 1 | $33 |
| Tolmar Pharmaceuticals, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Philips North America LLC | 1 | $19 |
| B. Braun Interventional Systems Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,884 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 15 | $193,652 |
| GemtesaVibegron | 64 | $41,553 |
| MyrbetriqMirabegron | 42 | $26,450 |
| Darifenacin ErDarifenacin Hydrobromide | 18 | $1,106 |
| Solifenacin Succinate | 25 | $866 |
| Tolterodine Tartrate ErTolterodine Tartrate | 14 | $747 |
| Tamsulosin Hcl | 42 | $518 |
| Finasteride | 14 | $188 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $182 |
| Desmopressin Acetate | 11 | $180 |
| Dutasteride | 12 | $130 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 12 | $100 |
| Levofloxacin | 26 | $56 |
| Sildenafil Citrate | 18 | $56 |
| Zolpidem Tartrate | 17 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $742 | $220,10257 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $467 | $41,55364 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.
Other family in Los Angeles
- Annette ShonLos Angeles$406K
- Phyllis CasonLos Angeles$187K
- Theodore SolomonLos Angeles$131K
- Angela SarffLos Angeles$51K
- Karla MenjivarLos Angeles$36K
- Janet GripshoverLos Angeles$30K
- Jualynda SmithLos Angeles$28K
- Phoebedel ReyesLos Angeles$26K
- Lori RobertsonChino Hills$475K
- Nancy GardettoSan Diego$394K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.